Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $35.50.

OPCH has been the topic of several research reports. JMP Securities reissued a "market outperform" rating and set a $36.00 target price on shares of Option Care Health in a research note on Tuesday, April 22nd. UBS Group upgraded Option Care Health from a "neutral" rating to a "buy" rating and upped their price target for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. Barrington Research restated an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. upped their price target on Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th.

Option Care Health Stock Performance

Shares of Option Care Health stock opened at $31.82 on Tuesday. Option Care Health has a 52 week low of $21.39 and a 52 week high of $35.53. The business's fifty day simple moving average is $32.20 and its 200-day simple moving average is $30.41. The firm has a market cap of $5.21 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 2.30 and a beta of 0.74. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the prior year, the company posted $0.26 EPS. The company's quarterly revenue was up 16.3% on a year-over-year basis. Equities analysts forecast that Option Care Health will post 1.22 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Murphy & Mullick Capital Management Corp purchased a new position in shares of Option Care Health in the 4th quarter valued at about $26,000. Signaturefd LLC grew its stake in Option Care Health by 487.9% during the 4th quarter. Signaturefd LLC now owns 1,211 shares of the company's stock worth $28,000 after buying an additional 1,005 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Option Care Health by 1,492.9% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock worth $31,000 after buying an additional 836 shares during the last quarter. Quadrant Capital Group LLC grew its stake in Option Care Health by 172.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock worth $40,000 after buying an additional 1,099 shares during the last quarter. Finally, Brooklyn Investment Group grew its stake in Option Care Health by 186.6% during the 1st quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after buying an additional 780 shares during the last quarter. Hedge funds and other institutional investors own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.